Literature DB >> 21452890

Polyoxazoline: chemistry, properties, and applications in drug delivery.

Tacey X Viegas1, Michael D Bentley, J Milton Harris, Zhihao Fang, Kunsang Yoon, Bekir Dizman, Rebecca Weimer, Anna Mero, Gianfranco Pasut, Francesco M Veronese.   

Abstract

Polyoxazoline polymers with methyl (PMOZ), ethyl (PEOZ), and propyl (PPOZ) side chains were prepared by the living cationic polymerization method and purified by ion-exchange chromatography. The following properties of polyoxazoline (POZ) were measured: apparent hydrodynamic radius by aqueous size-exclusion chromatography, relative lipophilicity by reverse-phase chromatography, and viscosity by cone-plate viscometry. The PEOZ polymers of different molecular weights were first functionalized and then conjugated to model biomolecules such as bovine serum albumin, catalase, ribonuclease, uricase, and insulin. The conjugates of catalase, uricase, and ribonuclease were tested for in vitro activity using substrate-specific reaction methods. The conjugates of insulin were tested for glucose lowering activity by injection to naïve Sprague-Dawley rats. The conjugates of BSA were injected into New Zealand white rabbits and serum samples were collected periodically and tested for antibodies to BSA. The safety of POZ was also determined by acute and chronic dosing to rats. The results showed that linear polymers of POZ with molecular weights of 1 to 40 kDa can easily be made with polydispersity values below 1.10. Chromatography results showed that PMOZ and PEOZ have a hydrodynamic volume slightly lower than PEG; PEOZ is more lipophilic than PMOZ and PEG; and PEOZ is significantly less viscous than PEG especially at the higher molecular weights. When PEOZ was attached to the enzymes catalase, ribonuclease, and uricase, the in vitro activity of the resultant bioconjugates depended on the extent of protein modification. POZ conjugates of insulin lowered blood glucose levels for a period of 8 h when compared to 2 h for insulin alone. PEOZ, like PEG, was also able to successfully attenuate the immunogenic properties of BSA. The POZ polymers (10 and 20 kDa) are safe when administered intravenously to rats, and the maximum tolerated dose (MTD) was greater than 2 g/kg. Blood counts, serum chemistry, organ weights, and the histopathology of key organs were normal. These results conclude that POZ has the desired drug delivery properties for a new biopolymer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21452890     DOI: 10.1021/bc200049d

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  41 in total

Review 1.  Protein-polymer conjugation-moving beyond PEGylation.

Authors:  Yizhi Qi; Ashutosh Chilkoti
Journal:  Curr Opin Chem Biol       Date:  2015-09-07       Impact factor: 8.822

2.  POxylation as an alternative stealth coating for biomedical applications.

Authors:  Herdis Bludau; Anna E Czapar; Andrzej S Pitek; Sourabh Shukla; Rainer Jordan; Nicole F Steinmetz
Journal:  Eur Polym J       Date:  2016-11-05       Impact factor: 4.598

3.  Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.

Authors:  Yang Liu; Juneyoung Lee; Kathryn M Mansfield; Jeong Hoon Ko; Sahar Sallam; Chrys Wesdemiotis; Heather D Maynard
Journal:  Bioconjug Chem       Date:  2017-01-03       Impact factor: 4.774

Review 4.  Design strategies for physical-stimuli-responsive programmable nanotherapeutics.

Authors:  Fitsum Feleke Sahle; Muhammad Gulfam; Tao L Lowe
Journal:  Drug Discov Today       Date:  2018-04-10       Impact factor: 7.851

5.  A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector.

Authors:  Zhijian He; Lei Miao; Rainer Jordan; Devika S-Manickam; Robert Luxenhofer; Alexander V Kabanov
Journal:  Macromol Biosci       Date:  2015-04-02       Impact factor: 4.979

6.  Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo.

Authors:  Jing Tong; Xiang Yi; Robert Luxenhofer; William A Banks; Rainer Jordan; Matthew C Zimmerman; Alexander V Kabanov
Journal:  Mol Pharm       Date:  2012-12-17       Impact factor: 4.939

Review 7.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

8.  Binding and biomimetic cleavage of the RNA poly(U) by synthetic polyimidazoles.

Authors:  Liang Cheng; K G Abhilash; Ronald Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

9.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes.

Authors:  Regina Tavano; Luca Gabrielli; Elisa Lubian; Chiara Fedeli; Silvia Visentin; Patrizia Polverino De Laureto; Giorgio Arrigoni; Alessandra Geffner-Smith; Fangfang Chen; Dmitri Simberg; Giulia Morgese; Edmondo M Benetti; Linping Wu; Seyed Moein Moghimi; Fabrizio Mancin; Emanuele Papini
Journal:  ACS Nano       Date:  2018-05-23       Impact factor: 15.881

Review 10.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.